Risk factors
Lexaria Bioscience (LEXX) risk factors
Item 1A of every Lexaria Bioscience Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors26 risks1 new1 reworded
Lexaria faces severe going concern doubts with only $1.8 million in cash against $1.5 million in liabilities, threatening operations. Growth depends heavily on costly R&D to prove DehydraTECH works with new APIs and molecules.
Filed Nov 28, 2025 - FY2024 10-K risk factors25 risks
Lexaxia relies heavily on the success, patent protection, and regulatory approval of its DehydraTECH drug delivery technology. The company faces significant financial constraints, early-stage preclinical pipeline risks, and evolving regulations governing cannabinoid products.
Filed Nov 26, 2024